RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists
Treating insulin resistance and type 2 diabetes in rodents, currently known retinoid X receptor (RXR) agonists induce significant adverse effects. Here we introduce a novel RXR partial agonist CBt-PMN (11b), which shows a potent glucose-lowering effect and improvements of insulin secretion and gluco...
Gespeichert in:
| Veröffentlicht in: | ACS medicinal chemistry letters 2012-05, Vol.3 (5), p.427-432 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 432 |
|---|---|
| container_issue | 5 |
| container_start_page | 427 |
| container_title | ACS medicinal chemistry letters |
| container_volume | 3 |
| creator | Kakuta, Hiroki Yakushiji, Nobumasa Shinozaki, Ryosuke Ohsawa, Fuminori Yamada, Shoya Ohta, Yui Kawata, Kohei Nakayama, Mariko Hagaya, Manabu Fujiwara, Chisa Makishima, Makoto Uno, Shigeyuki Tai, Akihiro Maehara, Ami Nakayama, Masaru Oohashi, Toshitaka Yasui, Hiroyuki Yoshikawa, Yutaka |
| description | Treating insulin resistance and type 2 diabetes in rodents, currently known retinoid X receptor (RXR) agonists induce significant adverse effects. Here we introduce a novel RXR partial agonist CBt-PMN (11b), which shows a potent glucose-lowering effect and improvements of insulin secretion and glucose tolerance without the serious adverse effects caused by RXR full agonists. We suggest that RXR partial agonists may be a new class of antitype 2 diabetes drug candidates. |
| doi_str_mv | 10.1021/ml300055n |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4025743</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1534095375</sourcerecordid><originalsourceid>FETCH-LOGICAL-a471t-a66474bed5587a05563ab2725a432de5b1b0955f744249628808661dc5777cf83</originalsourceid><addsrcrecordid>eNptkV1LwzAYhYMozq8L_4DkRtCLatImTXcjzLmp4Bc6wbuQtm9dpGtmkjr990amc4JXCXkfznlPDkK7lBxREtPjSZ0QQjhvVtAG7bIs4pngq0v3Dtp07oWQtCsEWUedmHUJYVm2gWb3T_f4TlmvVY17z6bRzuP-qY_urm_w4B2sd3g0Bqum0Hpd4EFVQRHeTINHH1PAMT7TKgcPDs-0H5vWYz8G_KBL-GUr_OUybOuFhdtGa5WqHex8n1vocTgY9S-iq9vzy37vKlJMUB-pNGWC5VDyEEOFiGmi8ljEXLEkLoHnNCddzivBWMiUxllGsjSlZcGFEEWVJVvoZK47bfMJlAU03qpaTq2eKPshjdLy76TRY_ls3iQjMRcsCQIH3wLWvLbgvJxoV0BdqwZM6yTlCQsrJIIH9HCOFtY4Z6Fa2FAiv4qSi6ICu7e814L8aSYA-3NAFU6-mNY24Zv-EfoEhWmZGQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1534095375</pqid></control><display><type>article</type><title>RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>American Chemical Society Journals</source><creator>Kakuta, Hiroki ; Yakushiji, Nobumasa ; Shinozaki, Ryosuke ; Ohsawa, Fuminori ; Yamada, Shoya ; Ohta, Yui ; Kawata, Kohei ; Nakayama, Mariko ; Hagaya, Manabu ; Fujiwara, Chisa ; Makishima, Makoto ; Uno, Shigeyuki ; Tai, Akihiro ; Maehara, Ami ; Nakayama, Masaru ; Oohashi, Toshitaka ; Yasui, Hiroyuki ; Yoshikawa, Yutaka</creator><creatorcontrib>Kakuta, Hiroki ; Yakushiji, Nobumasa ; Shinozaki, Ryosuke ; Ohsawa, Fuminori ; Yamada, Shoya ; Ohta, Yui ; Kawata, Kohei ; Nakayama, Mariko ; Hagaya, Manabu ; Fujiwara, Chisa ; Makishima, Makoto ; Uno, Shigeyuki ; Tai, Akihiro ; Maehara, Ami ; Nakayama, Masaru ; Oohashi, Toshitaka ; Yasui, Hiroyuki ; Yoshikawa, Yutaka</creatorcontrib><description>Treating insulin resistance and type 2 diabetes in rodents, currently known retinoid X receptor (RXR) agonists induce significant adverse effects. Here we introduce a novel RXR partial agonist CBt-PMN (11b), which shows a potent glucose-lowering effect and improvements of insulin secretion and glucose tolerance without the serious adverse effects caused by RXR full agonists. We suggest that RXR partial agonists may be a new class of antitype 2 diabetes drug candidates.</description><identifier>ISSN: 1948-5875</identifier><identifier>EISSN: 1948-5875</identifier><identifier>DOI: 10.1021/ml300055n</identifier><identifier>PMID: 24900488</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Letter</subject><ispartof>ACS medicinal chemistry letters, 2012-05, Vol.3 (5), p.427-432</ispartof><rights>Copyright © 2012 American Chemical Society</rights><rights>Copyright © 2012 American Chemical Society 2012 American Chemical Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a471t-a66474bed5587a05563ab2725a432de5b1b0955f744249628808661dc5777cf83</citedby><cites>FETCH-LOGICAL-a471t-a66474bed5587a05563ab2725a432de5b1b0955f744249628808661dc5777cf83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/ml300055n$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/ml300055n$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,2765,27076,27924,27925,53791,53793,56738,56788</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24900488$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kakuta, Hiroki</creatorcontrib><creatorcontrib>Yakushiji, Nobumasa</creatorcontrib><creatorcontrib>Shinozaki, Ryosuke</creatorcontrib><creatorcontrib>Ohsawa, Fuminori</creatorcontrib><creatorcontrib>Yamada, Shoya</creatorcontrib><creatorcontrib>Ohta, Yui</creatorcontrib><creatorcontrib>Kawata, Kohei</creatorcontrib><creatorcontrib>Nakayama, Mariko</creatorcontrib><creatorcontrib>Hagaya, Manabu</creatorcontrib><creatorcontrib>Fujiwara, Chisa</creatorcontrib><creatorcontrib>Makishima, Makoto</creatorcontrib><creatorcontrib>Uno, Shigeyuki</creatorcontrib><creatorcontrib>Tai, Akihiro</creatorcontrib><creatorcontrib>Maehara, Ami</creatorcontrib><creatorcontrib>Nakayama, Masaru</creatorcontrib><creatorcontrib>Oohashi, Toshitaka</creatorcontrib><creatorcontrib>Yasui, Hiroyuki</creatorcontrib><creatorcontrib>Yoshikawa, Yutaka</creatorcontrib><title>RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists</title><title>ACS medicinal chemistry letters</title><addtitle>ACS Med. Chem. Lett</addtitle><description>Treating insulin resistance and type 2 diabetes in rodents, currently known retinoid X receptor (RXR) agonists induce significant adverse effects. Here we introduce a novel RXR partial agonist CBt-PMN (11b), which shows a potent glucose-lowering effect and improvements of insulin secretion and glucose tolerance without the serious adverse effects caused by RXR full agonists. We suggest that RXR partial agonists may be a new class of antitype 2 diabetes drug candidates.</description><subject>Letter</subject><issn>1948-5875</issn><issn>1948-5875</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNptkV1LwzAYhYMozq8L_4DkRtCLatImTXcjzLmp4Bc6wbuQtm9dpGtmkjr990amc4JXCXkfznlPDkK7lBxREtPjSZ0QQjhvVtAG7bIs4pngq0v3Dtp07oWQtCsEWUedmHUJYVm2gWb3T_f4TlmvVY17z6bRzuP-qY_urm_w4B2sd3g0Bqum0Hpd4EFVQRHeTINHH1PAMT7TKgcPDs-0H5vWYz8G_KBL-GUr_OUybOuFhdtGa5WqHex8n1vocTgY9S-iq9vzy37vKlJMUB-pNGWC5VDyEEOFiGmi8ljEXLEkLoHnNCddzivBWMiUxllGsjSlZcGFEEWVJVvoZK47bfMJlAU03qpaTq2eKPshjdLy76TRY_ls3iQjMRcsCQIH3wLWvLbgvJxoV0BdqwZM6yTlCQsrJIIH9HCOFtY4Z6Fa2FAiv4qSi6ICu7e814L8aSYA-3NAFU6-mNY24Zv-EfoEhWmZGQ</recordid><startdate>20120510</startdate><enddate>20120510</enddate><creator>Kakuta, Hiroki</creator><creator>Yakushiji, Nobumasa</creator><creator>Shinozaki, Ryosuke</creator><creator>Ohsawa, Fuminori</creator><creator>Yamada, Shoya</creator><creator>Ohta, Yui</creator><creator>Kawata, Kohei</creator><creator>Nakayama, Mariko</creator><creator>Hagaya, Manabu</creator><creator>Fujiwara, Chisa</creator><creator>Makishima, Makoto</creator><creator>Uno, Shigeyuki</creator><creator>Tai, Akihiro</creator><creator>Maehara, Ami</creator><creator>Nakayama, Masaru</creator><creator>Oohashi, Toshitaka</creator><creator>Yasui, Hiroyuki</creator><creator>Yoshikawa, Yutaka</creator><general>American Chemical Society</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20120510</creationdate><title>RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists</title><author>Kakuta, Hiroki ; Yakushiji, Nobumasa ; Shinozaki, Ryosuke ; Ohsawa, Fuminori ; Yamada, Shoya ; Ohta, Yui ; Kawata, Kohei ; Nakayama, Mariko ; Hagaya, Manabu ; Fujiwara, Chisa ; Makishima, Makoto ; Uno, Shigeyuki ; Tai, Akihiro ; Maehara, Ami ; Nakayama, Masaru ; Oohashi, Toshitaka ; Yasui, Hiroyuki ; Yoshikawa, Yutaka</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a471t-a66474bed5587a05563ab2725a432de5b1b0955f744249628808661dc5777cf83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Letter</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kakuta, Hiroki</creatorcontrib><creatorcontrib>Yakushiji, Nobumasa</creatorcontrib><creatorcontrib>Shinozaki, Ryosuke</creatorcontrib><creatorcontrib>Ohsawa, Fuminori</creatorcontrib><creatorcontrib>Yamada, Shoya</creatorcontrib><creatorcontrib>Ohta, Yui</creatorcontrib><creatorcontrib>Kawata, Kohei</creatorcontrib><creatorcontrib>Nakayama, Mariko</creatorcontrib><creatorcontrib>Hagaya, Manabu</creatorcontrib><creatorcontrib>Fujiwara, Chisa</creatorcontrib><creatorcontrib>Makishima, Makoto</creatorcontrib><creatorcontrib>Uno, Shigeyuki</creatorcontrib><creatorcontrib>Tai, Akihiro</creatorcontrib><creatorcontrib>Maehara, Ami</creatorcontrib><creatorcontrib>Nakayama, Masaru</creatorcontrib><creatorcontrib>Oohashi, Toshitaka</creatorcontrib><creatorcontrib>Yasui, Hiroyuki</creatorcontrib><creatorcontrib>Yoshikawa, Yutaka</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>ACS medicinal chemistry letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kakuta, Hiroki</au><au>Yakushiji, Nobumasa</au><au>Shinozaki, Ryosuke</au><au>Ohsawa, Fuminori</au><au>Yamada, Shoya</au><au>Ohta, Yui</au><au>Kawata, Kohei</au><au>Nakayama, Mariko</au><au>Hagaya, Manabu</au><au>Fujiwara, Chisa</au><au>Makishima, Makoto</au><au>Uno, Shigeyuki</au><au>Tai, Akihiro</au><au>Maehara, Ami</au><au>Nakayama, Masaru</au><au>Oohashi, Toshitaka</au><au>Yasui, Hiroyuki</au><au>Yoshikawa, Yutaka</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists</atitle><jtitle>ACS medicinal chemistry letters</jtitle><addtitle>ACS Med. Chem. Lett</addtitle><date>2012-05-10</date><risdate>2012</risdate><volume>3</volume><issue>5</issue><spage>427</spage><epage>432</epage><pages>427-432</pages><issn>1948-5875</issn><eissn>1948-5875</eissn><abstract>Treating insulin resistance and type 2 diabetes in rodents, currently known retinoid X receptor (RXR) agonists induce significant adverse effects. Here we introduce a novel RXR partial agonist CBt-PMN (11b), which shows a potent glucose-lowering effect and improvements of insulin secretion and glucose tolerance without the serious adverse effects caused by RXR full agonists. We suggest that RXR partial agonists may be a new class of antitype 2 diabetes drug candidates.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>24900488</pmid><doi>10.1021/ml300055n</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1948-5875 |
| ispartof | ACS medicinal chemistry letters, 2012-05, Vol.3 (5), p.427-432 |
| issn | 1948-5875 1948-5875 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4025743 |
| source | EZB-FREE-00999 freely available EZB journals; PubMed Central; American Chemical Society Journals |
| subjects | Letter |
| title | RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T07%3A19%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=RXR%20Partial%20Agonist%20CBt-PMN%20Exerts%20Therapeutic%20Effects%20on%20Type%202%20Diabetes%20without%20the%20Side%20Effects%20of%20RXR%20Full%20Agonists&rft.jtitle=ACS%20medicinal%20chemistry%20letters&rft.au=Kakuta,%20Hiroki&rft.date=2012-05-10&rft.volume=3&rft.issue=5&rft.spage=427&rft.epage=432&rft.pages=427-432&rft.issn=1948-5875&rft.eissn=1948-5875&rft_id=info:doi/10.1021/ml300055n&rft_dat=%3Cproquest_pubme%3E1534095375%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1534095375&rft_id=info:pmid/24900488&rfr_iscdi=true |